dihexa human studies clinical trials or dihexa human clinical trials or studies dihexa clinical trials status dihexa human trials status 2026 SCOPE First-In-Human Clinical Trial Requirement -BioPharma

Advantage : CagriSema Weight Loss Efficacy# CagriSema : REDEFINE 1 demonstrated 20.4% mean weight loss at 68 weeks in adults without T2D

A., Reedtz-Runge, S., Glendorf, T., Ballarn-Gonzlez, B., Raun, K., Bayly-Jones, C., Wootten, D., & Sexton, P

showed that dual blockade of SU11274 (c-MET inhibitor) and erlotinib (EGFR inhibitor) in HNSCC lines produce greater-than-additive inhibition of cell growth via erbB3/AKT signaling [86]

Sikiric P, Gojkovic S, Krezic I, Smoday IM, Kalogjera L, Zizek H, Oroz K, Vranes H, Vukovic V, Labidi M, Strbe S, Baketic Oreskovic L, Sever M, Tepes M, Knezevic M, Barisic I, Blagaic V, Vlainic J, Dobric I, Staresinic M, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S

Its role in the adult brain involves supporting neuronal survival, promoting synaptic plasticity, and facilitating neurogenesis -- functions that make it a plausible target for cognitive enhancement